Oasis Tears PF, 10mL recall — Oasis Medical, Inc. (Class II)
Oasis Medical, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Oasis Tears PF, 10mL — a Class II recall, initiated 2026-04-27 and posted to the FDA enforcement report on 2026-05-20, under recall number D-0525-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision.”. From the product description, the form is eye drops, the strength given is 10mL and the package is described as 0.34 Fl OZ Bottle. 1 National Drug Code number is printed in the record: 42126-6400-1. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in CA, United States. It is the only recall number the FDA has filed under event ID 98897. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0525-2026 |
|---|---|
| FDA event ID | 98897 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Oasis Medical, Inc. |
| Recall initiated | 2026-04-27 |
| Reported by FDA | 2026-05-20 |
| Report lag | 23 days from initiation to report |
| Distribution | Nationwide within the United States — Nationwide (US) |
| Firm location on record | CA, United States |
| Product description (source) | Oasis Tears PF, Preservative-Free Lubricant Eye Drops, 10mL/0.34 Fl OZ Bottle, Sterile, Manufactured for: OASIS Medical, Inc., 514 S. Vermont Ave., Glendora, CA 91741, USA, Made in France, NDC 42126-6400-1. |
Reason reported by FDA
Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision.
26 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
6 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.
| Product named | Oasis Tears PF |
|---|---|
| Form | Eye Drops |
| Strength | 10mL |
| Package | 0.34 Fl OZ Bottle |
| NDC | 42126-6400-1 |
| Stated origin | France |
| Manufactured for | OASIS Medical, Inc. |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Buprenorphine Hydrochloride, 0.3mg/mL | D-0527-2026 | Endo Usa, Inc. | Class II | 2026-05-20 |
| Ascend Laboratories, 25 mg | D-0547-2026 | Ascend Laboratories, LLC | Class II | 2026-05-20 |
| DELFLEX, 1.5% | D-0512-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| DELFLEX, 2.5% | D-0513-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 30 mg | D-0514-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 60 mg | D-0515-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 20 mg | D-0516-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| BD PurPrep, 8.3% | D-0517-2026 | Carefusion 213, LLC | Class II | 2026-05-13 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-20 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| BD PurPrep, 8.3% | D-0518-2026 | Carefusion 213, LLC | 8.3% · Solution | 2026-05-13 |
| Octreotide Acetate for Injectable Suspension, 30 mg | D-0519-2026 | Teva Pharmaceuticals Usa, Inc | 30 mg · Injectable Suspension | 2026-05-13 |
| Enalapril Maleate Tablets, 20 mg | D-0520-2026 | JB Chemicals And Pharmaceuticals Ltd | 20 mg · Tablets | 2026-05-13 |
| Duloxetine Delayed-Release Capsules USP, 60mg | D-0522-2026 | Breckenridge Pharmaceutical, Inc. | 60mg · Delayed-Release Capsules | 2026-05-13 |
| NAPROXEN ORAL SUSPENSION, 125 mg/5mL | D-0523-2026 | Acella Pharmaceuticals, LLC | 125 mg/5mL · Oral Suspension | 2026-05-13 |
| TPN bag (patient specific), 1660 mL | D-0524-2026 | Central Admixture Pharmacy Services, Inc (caps) Los Angeles | 1660 mL · Injection | 2026-05-13 |
| Atomoxetine Capsules HCL, 10 mg | D-0538-2026 | Safecor Health, LLC | 10 mg · Capsules | 2026-05-27 |
| Liraglutide Injection, 18 mg/3 mL | D-0541-2026 | Lupin Pharmaceuticals Inc. | 18 mg/3 mL · Injection | 2026-05-27 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 42126-6400-1 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Oasis Medical, Inc. (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0525-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0525-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-20
- Ingested
- 2026-08-22
- Record hash
c63444bb2d542cf0
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.